Abstract
Lung cancer remains the most common cause of cancer death globally. Dysregulation of immune response and inflammatory signaling is known to play an important role in lung tumorigenesis, but the causal drivers of this process have yet to be elucidated. To identify circulating inflammatory and immune-related proteins that influence risk for lung cancer we related genetically predicted plasma levels for 85 inflammation and immune proteins with susceptibility to lung cancer. Mendelian randomization (MR) analyses in 29,266 cases and 56,450 controls identified a candidate causal marker, IL-18, which conferred lower risk of lung cancer (OR per standard deviation increase: 0.85 [95% CI: 0.79-0.92]), in particular for adenocarcinoma (OR: 0.80 [95% CI: 0.72-0.89]). We subsequently validated this association using polygenic IL-18 predictions in the UK Biobank (HR highest vs. lowest quartile: 0.83 [95% CI: 0.72-0.95]) and using pre-diagnostic blood concentrations of IL-18 in 732 cases and 732 controls after controlling for the inhibitory role of IL-18BP (OR highest vs. lowest quartile: 0. 63 [95% CI: 0. 41-0.91]). Genetic colocalization suggested that IL-18 may act on lung cancer risk locally via lung tissue expression, and joint MR and tumor microenvironment analyses highlight CD8 T cells and NK cells as potential mediators. In addition to risk, IL-18 expression in adenocarcinoma tumor tissue was found to be associated with all-cause mortality in 480 TCGA samples after controlling for IL-18BP (HR per SD: 0.87 [95% CI: 0.78, 0.98]), which is in line with recent studies showing anti-tumor effects of IL-18. Our comprehensive genomic triangulation study thus highlights the potential for IL-18 as an aetiological biomarker and targetable for immune-oncology therapies.
Competing Interest Statement
Anders Malarstig is a current employee of Pfizer R&D. The other authors have no conflict of interest to declare.
Funding Statement
This research was supported by funding from the US National Institutes of Health (INTEGRAL Program grant U19 CA203654) and Cancer Research UK (C18281/A29019). We would additionally like to acknowledge the SCALLOP and ILCCO consortia for generating the extensive summary statistics making the discovery analysis possible.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Each contributing study for the nested case-control protein study has been approved by the Ethical Committees of the original contributing studies: The European Investigation into Cancer and Nutrition; The Northern Sweden Health and Disease Study; The Trondelag Health Study; The Cancer Prevention Study II; The Singapore Chinese Health Study; The Melbourne Collaborative Cohort Study. Genetic analyses were approved by the ILCCO consortium.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared first authorship
Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.
Data Availability
Summary statistics are freely available for protein GWAS from Folkersen et al. and for tumor immune characteristics from Sayaman et al.. Summary statistics for risk for lung cancer are available upon successful application to the ILCCO consortium. Individual-level patient characteristics for the Cancer Genome Atlas are available for download from dbGap. Individual-level protein data from the nested case-control studies are part of an ongoing study (INTEGRAL Project 2, U19 CA203654). These data will be available for analysis by investigators outside the study folllowing the date of publication of final results from the study's validation phase.
https://www.nature.com/articles/s42255-020-00287-2
https://www.sciencedirect.com/science/article/abs/pii/S1074761321000340
Data Availability
Anonymized data will be shared by reasonable request from any qualified investigator.
